LIFE: Lifecare BoD propose a partially underwritten rights issue

Bergen, Norway, 26 April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), intent to invite its existing shareholders in a NOK 90 million partially underwritten rights issue.

The proposed rights issue will ensure preferential subscription rights for existing shareholders, with already underwritten guarantees a minimum of NOK 75 million. Subscribers in the rights issue will without cost be allocated warrants giving the holder right to subscribe for new shares when exercisable. The detailed terms for the rights and warrant issue are available in the stock exchange notification.

– The progress plans in Lifecare are going according to schedule and we have been delivering milestones on a continuous basis over a long period. This issue will give the company a strengthened financial backbone and, most importantly, fully secure the funding of the company until our sensor technology is launched in the commercial market, says CEO Joacim Holter at Lifecare.

– We want to ensure fair and equal treatment of our loyal base of shareholders, and the proposed rights issue is designed to do just that, says Joacim Holter. One advantage of the guaranteed fundraising structure is that the company can confirm sufficient funding when we now announce the intentions. Furthermore, a rights issue is a shareholder-friendly form of transaction as existing shareholders have preferential rights to subscribe in the offering.

This rights issue is also important considering that Lifecare is in the process of applying for uplisting from Euronext Growth to the main list on Oslo Stock Exchange. – Completion of a partially underwritten rights issue will ensure compliance of financial requirements for listing on Oslo Stock Exchange. We expect that a listing on the main list at Oslo Stock Exchange will further accelerate the overall growth of our company, attract, and secure a more flexible and even broader investor base that will support Lifecare in reaching our growth targets. We also expect that an uplisting will increase share liquidity and strengthen the profile of Lifecare, says Holter.

About us
Lifecare AS is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

Asle Wingsternes, Head of Communications & Public Affairs, asle.wingsternes@lifecare.no, +47 41 61 42 52

Attachments
LIFE: Lifecare BoD propose a partially underwritten rights issue

LIFE: Lifecare BoD propose a partially underwritten rights issue